Alternatives to EllieMD

The complete ladder is on the page before any intake, which almost nothing else here does: semaglutide $199 a month, $549 for three months, $999 for six, $1,788 for twelve; tirzepatide $299, $797, $1,494, $2,748. Read the long tiers correctly — each is a single upfront charge rather than a smaller monthly bill, so the advertised $149 means paying a full year before the first box ships. Disclosure is above average where it counts. Andrew Meds LLC is named with a Houston address, and the practice that writes the prescription is named separately as Dr Tel X in Kennewick, Washington. Coverage is all fifty states and DC, enumerated rather than claimed, and there is an oral tirzepatide alongside the injections. The gaps: the compounding pharmacy is never named, no time to first dose is published, and a period you have partly used is not refunded.

$114 is the lowest semaglutide figure on this page, and it comes with a condition SurpassMD prints only in its FAQ: the price applies "for eligible patients with a promotion". The standing rate is published nowhere, which makes budgeting past the first cycle guesswork. What is solid: all fifty states plus DC, 503A compounding, cold-chain shipping within 48 hours of approval, HSA and FSA accepted, cancel anytime. There is an oral semaglutide as well, with no price attached.

If injections are the blocker, this is the one to look at: DoctorAdam sells GLP-1s only as daily oral tablets, with no injectable in the catalog at all. Semaglutide tablets from $129 a month, tirzepatide tablets from $199, all fifty states, flat monthly pricing with no hidden fees. It also names its clinicians and publishes an Anaheim address. One caution when reading the grid: NAD+ injections carry the same $129 and sit near the semaglutide card.

A science-forward compounded shop with a broad peptide catalog and flat dosing — $170/mo semaglutide, $210/mo tirzepatide ongoing — but the homepage 'as low as' price is a promotional rate, and the compounding pharmacy isn't named.

The arithmetic that stands out: tirzepatide costs the same as semaglutide here, both from $169 a month, where the dual agonist normally carries a $50 to $100 premium. Over a year that is a real difference. Lighter You also names four compounding pharmacies outright — RedRock, Health Warehouse, Precision Compounding and Triad Rx — with websites, addresses and phone numbers, where most of this roster names none. All fifty states plus Washington, D.C.

A genuinely transparent tiered-pricing shop — as low as $149/mo semaglutide or $199/mo tirzepatide on the annual plan — with press mentions and bilingual support, though the oral tablet's own pricing wasn't fully itemized.

Three clear prices — $150, $240, and $150 for an oral liposomal semaglutide — attached to statistics that do not survive checking. The "94.6% success rate" is footnoted to "approximately 66,260 Remedy Meds members", the white-label platform this site runs on rather than its own patients; a second footnote says 50,000. The live review widget reads six reviews, one member, beneath "1M+ Users on GLP-1".

A granular GLP-1 menu — microdose from $129/mo, semaglutide from $149/mo, tirzepatide from $249/mo, plus an exclusive combined 'GLP-Squared' injection — all stated as all-inclusive, though the site doesn't itemize exactly what that covers.

There is no way to price Believe without applying to it. Its three GLP-1 treatment pages were read end to end and carry no dollar figure at all; the only number on the homepage is a badge promising nothing is charged if you are not approved. Behind the eligibility gate the menu is four plans, each flat at every dose: semaglutide $149 a month against a struck-through $249, tirzepatide $229 against $299 and marked most chosen, a microdose at $199, and a daily oral at $229. Those are competitive figures with two complications. The microdose costs $50 a month more than standard semaglutide, the reverse of what a lower dose implies. And two of the four plans never name a molecule, so you would be choosing between products without being told which drug is in them. It claims fifty-state care without listing states, names no pharmacy, and publishes no time to first dose.